Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Cholinesterase inhibitors for Alzheimer's disease
Autore:
Grutzendler, J; Morris, JC;
Indirizzi:
Washington Univ, Sch Med, Alzheimer Dis Res Ctr, St Louis, MO 63110 USA Washington Univ St Louis MO USA 63110 Dis Res Ctr, St Louis, MO 63110 USA Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA Washington Univ St Louis MO USA 63110 Dept Neurol, St Louis, MO 63110 USA
Titolo Testata:
DRUGS
fascicolo: 1, volume: 61, anno: 2001,
pagine: 41 - 52
SICI:
0012-6667(2001)61:1<41:CIFAD>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
CONTROLLED-RELEASE PHYSOSTIGMINE; RANDOMIZED CONTROLLED TRIAL; MUSCARINIC AGONIST THERAPY; AMYLOID PRECURSOR PROTEIN; DOUBLE-BLIND; GLOBAL FUNCTION; SYNAPSE LOSS; TACRINE; DONEPEZIL; SYMPTOMS;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
75
Recensione:
Indirizzi per estratti:
Indirizzo: Grutzendler, J Washington Univ, Sch Med, Alzheimer Dis Res Ctr, Campus Box8111-MDC,660 SEuclid Ave, St Louis, MO 63110 USA Washington Univ Campus Box 8111-MDC,660 S Euclid Ave St Louis MO USA 63110
Citazione:
J. Grutzendler e J.C. Morris, "Cholinesterase inhibitors for Alzheimer's disease", DRUGS, 61(1), 2001, pp. 41-52

Abstract

Alzheimer's disease (AD) is the most common age-related neurodegenerative disease and has become an urgent public health problem in most areas of theworld. Substantial progress has been made in understanding the basic neurobiology of AD and, as a result, new drugs for its treatment have become available. Cholinesterase inhibitors (ChEIs), which increase the availability of acetylcholine in central synapses, have become the main approach to symptomatic treatment. ChEIs that have been approved or submitted to the US Food and Drug Administration (FDA) include tacrine, donepezil, metrifonate, rivastigmine and galantamine. In this review we discuss their pharmacology, clinical experience to date with their use and their potential benefits or disadvantages. ChEIs have a significant, although modest, effect on the cognitive status of patients with AD. in addition to their effect on cognition,ChEIs have a positive effect on mood and behaviour. Uncertainty remains about the duration of the benefit because few studies of these compounds beyond one year have been published. Although ChEIs are generally well tolerated, all patients should be followed closely for possible adverse effects. There is no substantial difference in the effectivenes of the various ChEIs, however, they may have different safety profiles. We believe the benefits of their use outweigh the risks and costs and, therefore, ChEIs should be considered as primary therapy for patients with mild to moderate AD.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/09/20 alle ore 23:23:40